Description
The Gene Verification Committee (GVC) reviews published human genetic evidence to determine whether specific loci or genes are associated with Alzheimer's disease (AD) or dementia and contribute to disease risk. The GVC uses two complementary variant- and aggregate-based evaluation frameworks, designating associations as having sufficient, suggestive, limited, or insufficient evidence, to evaluate the quality of genetic support and to prioritize loci and genes for investment in functional genomic studies and downstream therapeutic target selection.